Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
NCT03030287 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG OMP-305B83
Study Locations (7)
Colorado
- University of Colorado, Anschutz Medical Campus — Aurora
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt Cancer Center) — Tampa
North Carolina
- Levine Cancer Institute — Charlotte
Oklahoma
- Stephenson Cancer Center — Oklahoma City
Pennsylvania
- The University of Pennsylvania Health System — Philadelphia
Tennessee
- Tennessee Oncology, PLLC — Nashville
Texas
- The University of Texas, MD Anderson Cancer Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030287
The ClinicalTrials.gov registry entry for NCT03030287 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Cancer Ovaries appearing as the primary indexed condition, and to 2 interventions — of which Paclitaxel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03030287 reports 7 study locations spanning 7 distinct geographic areas — top geographies include Colorado, Florida, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03030287 about?
NCT03030287 is a clinical study titled "A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer". The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may b...
What is the current status of trial NCT03030287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-12. Estimated completion is 2020-04.
What conditions does trial NCT03030287 study?
This clinical trial studies the following conditions: Cancer Ovaries, Cancer Peritoneal, Cancer, Fallopian Tube. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03030287?
The interventions under investigation include: Paclitaxel (DRUG), OMP-305B83 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03030287?
This trial is sponsored by OncoMed Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03030287 being conducted?
This trial has 7 study locations across Colorado, Florida, North Carolina, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.